The current treatment landscape of mHSPC

EP: 1.The Incidence of Prostate Cancer and Risk of Progression in Black Men

EP: 2.Factors Contributing to Higher Incidence and Worse Outcomes of mHSPC in Black Men

EP: 3.Representation of Black men with mHSPC in clinical trials

Now Viewing

EP: 4.The current treatment landscape of mHSPC

EP: 5.Efficacy outcomes in Black patients from the ARANOTE trial

EP: 6.Safety data on Black patients from ARANOTE

EP: 7.Comparing the safety profile of darolutamide with other androgen receptor inhibitors in Black patients

EP: 8.Outcomes in Black patients receiving darolutamide plus ADT for mHSPC

EP: 9.Translating the Trial: How Findings from ARANOTE May Inform Treatment Decisions

EP: 10.The importance of studying efficacy and safety of treatment in Black patients with mHSPC

EP: 11.Improving diversity in future clinical trials for mHSPC

EP: 12.Remaining unmet needs in diverse populations with mHSPC

Treatment Options for mHSPC

Key Themes:

• Current 2025 guidelines recommend ADT with intensification.
• Multiple intensification options include abiraterone, darolutamide, and docetaxel.
• Key clinical trials include ARANOTE, ARASENS, and TITAN.
• All studies demonstrate survival benefit and delayed disease progression with intensification.

Key Points for Physicians:

• ADT monotherapy is no longer the standard of care.
• Multiple evidence-based intensification options exist.
• Selection can be tailored based on patient characteristics and preferences.
• All intensification approaches demonstrate benefit over ADT alone.

Notable Insights: The evolution to combination therapy approaches represents a significant paradigm shift in the management of mHSPC, with multiple effective options now available.

Clinical Significance: The established benefit of intensification therapy has fundamentally changed the treatment landscape for mHSPC, providing multiple evidence-based approaches to improve outcomes.